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What I find most interesting about feline diabetes 
Claudia E. Reusch 
During the last years our diabetes group in Zurich has investigated three main topics: (1) 
characterization of β-cell damage in feline diabetes, (2) treatment protocols to increase 
remission rates and (3) tools for diabetes monitoring.  
(1) The classification of diabetes mellitus in cats has traditionally followed the scheme used in 
humans, where the main categories are type 1 diabetes, type 2 diabetes, specific types of 
diabetes due to other causes and gestational diabetes. Type 2 diabetes is the most common 
form and is due to a progressive insulin secretory defect on the background of insulin 
resistance (ADA, 2015). It is currently assumed, that a large percentage of diabetic cats suffer 
from a type 2-like diabetes mellitus. So far, very little work has been done on β-cell function 
and insulin secretion in cats with natural development of diabetes. The big question: “What 
exactly leads to β-cell failure under natural conditions?” is unanswered until today. It is 
known for quite some time that chronic hyperglycemia has damaging effects on β-cells, 
known under the umbrella term of glucotoxicity. We recently investigated glucose-induced 
lesions in healthy cats by maintaining blood glucose constantly between 25 – 30 mmol/l for a 
period of 10 days.  Already 2 days after the beginning of the glucose clamp insulin levels 
started to decline and dropped to close to the detection limit of the assay. After 10 days of 
hyperglycemia β-cells were reduced by 50% compared to controls. Islet cells showed 
apoptotic features and were caspase-3 (a marker for apoptosis) positive. Additionally, 
hyperglycemia induced a systemic inflammatory response, characterized by an increase of α1-
acid glycoprotein (Zini et al, 2009). The concept of glucotoxicity is very important to 
understand because immediate treatment of diabetes may reverse (at least in part) the negative 
effects of glucose on β-cells and increase the chance of diabetic remission. However, it is 
clear, that glucotoxicity is a secondary event, because hyperglycemia becomes apparent only 
after β-cells start to fail.  One long-known hypothesis concerns β-cell destruction by amyloid 
deposition. Only cats, humans and nonhuman primates have an amyloidogenic amino acid 
structure of amylin, which is stored together with insulin in secretory vesicles and is co-
secreted with insulin. Interestingly, however, amyloid deposits were similar in diabetic cats 
and matched control cats. Neither the frequency of amyloid deposits (54% of diabetic cats, 
40% of controls) nor the extent of amyloid deposition differed between the groups (Zini et al, 
2016). As result of this study, we hypothesize that amyloid deposits within the islets (i.e. 
around the β-cells) are not the primary cause of β-cell failure.  Studies are underway to 
investigate the role of so-called toxic oligomers of amylin within the β-cells in the 
pathogenesis of feline diabetes.  
(2) Remission of diabetes is defined as a situation in which clinical signs of diabetes 
disappear, blood glucose concentration normalizes and insulin treatment can be discontinued. 
In human medicine, the duration of normoglycemia has to be at least one year to be labelled 
remission (Buse et al, 2009). In cats, there is not yet an agreement of the time period. In 
Zurich we use a cut-off of 4 weeks as criterion, i.e. the disease-free interval has to last for a 
minimum of 4 weeks before the diabetes is considered to be in remission (Sieber-Ruckstuhl et 
al, 2008). Remission is increasingly recognized and it is assumed that good glycemic control 
improves β-cell function most likely due to abolishment of the damaging effects of high blood 
glucose on β-cell function. Cats which do not experience diabetic remission may be in a more 
advanced stage of their disease with more pronounced β-cell loss or suffer from substantial 
concurrent disease. Diabetic remission most often occurs during the first three to four months 
of therapy. Consequently, the first months after diagnosis is the most important time during 
management of diabetes. We recently investigated, if initial constant intravenous insulin 
application (insulin aspart) over 1 week decreases subsequent insulin requirements and 
increases remission rate. Overall, 87% of cats of the IV group achieved good metabolic 
control or diabetic remission compared to 57% in the group of cats receiving insulin glargine 
BID. Insulin dose given during the 6-month follow-up was significantly lower in the IV 
group. We attributed the beneficial effect to improved β-cell function similar to what has been 
shown in human diabetics treated with initial intensive IV insulin protocols (Hafner et al, 
2014).  As this approach is labour and cost intensive other treatment modalities are under 
investigation. A similar beneficial effect was found in a pilot study, when a GLP-1 analogue 
(Exenatide extended release SC once per week) was added to our standard protocol (insulin 
glargine BID, low-carbohydrate diet). 93% of the insulin + GLP-1 group achieved good 
metabolic control or diabetic remission, compared to 67% in the insulin only group (Riederer 
et al, 2016).  Other investigators have shown that remission rates in diabetic cats treated with 
insulin glargine or detemir and low-carbohydrate diet are high when glucose targets are set 
very low (Roomp and Rand, 2009 and 2012; Nack and DeClue, 2014). The challenge for the 
future will be to find treatment protocols which are safe (i.e. avoid hypoglycaemia) and give 
the greatest benefit for the patient (i.e. achieve high remission rates). 
(3) The fine-tuning of therapy requires measurement of blood glucose and the generation of 
blood glucose curves. The first manuscript on capillary blood sampling (Wess and Reusch, 
2000) was very difficult to get published, because the editor thought that owners would never 
do blood sampling on their pets. In the meantime, home-monitoring (HM) developed into a 
routinely used monitoring tool. However, HM is not without challenges: variability of BGC is 
high (Alt et al, 2007), opinions on frequency of monitoring differ largely and quality control 
of the glucometer is a continuous concern. To overcome some of the problems with traditional 
HM we recently validated a continuous glucose monitoring system (CGMS) for use at home 
(Salesov et al, submitted). The first series of results in diabetic cats are promising.  
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